Biopharma Quarterly Dealmaking Statistics, Q2 2016
A look at financing, M&A and alliance activity April–June 2016
Biopharma financing decreased by 16% in Q2 to $4.8 billion, while the total value of acquisitions nearly doubled to $22 billion, including AbbVie's $9.8 billion takeover of Stemcentrx. Alliances garnered an aggregate potential deal value of $23.1 billion, led by Allergan's CNS agreement with Heptares.
You may also be interested in...
Two manufacturing control assays have taken longer to develop than previously thought, putting back completion of a BLA submission to early 2017 for US company Spark Therapeutics, while further progress has been made in the company’s early-stage hemophilia gene therapy program.
Bioverativ was unveiled as the name for Biogen’s spin out; an initial Form 10 registration will be filed with SEC later this week.
Record-setting divestment order driven by sheer number of products where firms competed, not size of company that would result from acquisition.